

Press release – No. 03 / 2020

## Zealand Pharma to attend Credit Suisse 2020 Global Healthcare Conference

---

*Copenhagen, February 27, 2020* – Executive Vice President, Research & Development and Chief Medical Officer Adam Steensberg plans to attend the Credit Suisse 2020 Global Healthcare Conference on March 4, 2020 in London.

Please refer to the [conference website](#) for information and updated schedules.

**For further information, please contact:**

**Zealand Pharma Investor Relations**

+45 50 60 38 00 [investors@zealandpharma.com](mailto:investors@zealandpharma.com)

**Lani Pollworth Morvan**, Investor Relations and Communication

[lpm@zealandpharma.com](mailto:lpm@zealandpharma.com)

**About Zealand Pharma A/S**

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand's current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand's portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit [www.zealandpharma.com](http://www.zealandpharma.com) or follow Zealand on LinkedIn or Twitter @ZealandPharma.